Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments: 2018-2025

Historic Cash & Current Investments for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $235.4 million.

  • Arcturus Therapeutics Holdings' Cash & Current Investments fell 19.45% to $235.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 20.43%. This contributed to the annual value of $292.0 million for FY2024, which is 16.30% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Cash & Current Investments of $235.4 million as of Q3 2025, which was down 6.41% from $251.5 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Cash & Current Investments ranged from a high of $466.8 million in Q1 2021 and a low of $235.4 million during Q3 2025.
  • For the 3-year period, Arcturus Therapeutics Holdings' Cash & Current Investments averaged around $299.8 million, with its median value being $311.9 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 684.99% in 2021, then crashed by 42.57% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash & Current Investments (Quarterly) stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then fell by 10.97% to $348.9 million in 2023, then dropped by 16.30% to $292.0 million in 2024, then decreased by 19.45% to $235.4 million in 2025.
  • Its Cash & Current Investments was $235.4 million in Q3 2025, compared to $251.5 million in Q2 2025 and $255.4 million in Q1 2025.